Interestingly, we found that, in RWPE1, the immortalized prostate epithelial cell, which expresses a high level of ASS1 and is non-arginine auxotrophic, silencing TEAD4 in RWPE1 cell did not significantly affect the OXPHOS expression either at the transcript or at the protein level, suggesting that the requirement of TEAD4 to activate nuclear OXPHOS genes is tumor selective (Supplementary Fig. 2d, e), which renders TEAD4 as a potential therapeutic target for prostate cancer. The gene discussed is ASS1; the disease is prostate cancer.